Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial
Authors
Keywords
-
Journal
Modern Rheumatology
Volume 26, Issue 6, Pages 900-907
Publisher
Informa UK Limited
Online
2016-03-03
DOI
10.3109/14397595.2016.1160968
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Corticosteroid- and cyclophosphamide-free treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis using tocilizumab
- (2015) Ryota Sakai et al. Modern Rheumatology
- Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab
- (2015) Alvise Berti et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response
- (2015) Jun Kikuchi et al. ARTHRITIS RESEARCH & THERAPY
- Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
- (2015) Ryoko Sakai et al. ARTHRITIS RESEARCH & THERAPY
- Limitations of Standard Immunosuppressive Treatment in ANCA-Associated Vasculitis and Lupus Nephritis
- (2015) Vladimir Tesar et al. NEPHRON CLINICAL PRACTICE
- Therapeutic uses of anti-interleukin-6 receptor antibody
- (2014) S. Kang et al. INTERNATIONAL IMMUNOLOGY
- Significance of Small Renal Artery Lesions in Patients with Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis
- (2014) A. Endo et al. JOURNAL OF RHEUMATOLOGY
- Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis
- (2014) Ryuji Koike et al. Modern Rheumatology
- Key advances in the clinical approach to ANCA-associated vasculitis
- (2014) Cees G. M. Kallenberg Nature Reviews Rheumatology
- Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study
- (2014) Ken-ei Sada et al. ARTHRITIS RESEARCH & THERAPY
- Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray
- (2014) Yoshie Sanayama et al. Arthritis & Rheumatology
- State of the Art in the Treatment of Systemic Vasculitides
- (2014) Raashid Ahmed Luqmani Frontiers in Immunology
- Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases
- (2013) Rieke Alten et al. ANNALS OF MEDICINE
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
- (2013) Marie B Condon et al. ANNALS OF THE RHEUMATIC DISEASES
- Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy
- (2013) Naoshi Nishina et al. ANNALS OF THE RHEUMATIC DISEASES
- Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab
- (2013) Kenchi Takenaka et al. CLINICAL RHEUMATOLOGY
- Treatment of ANCA-associated vasculitis
- (2013) Ulf Schönermarck et al. Nature Reviews Nephrology
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
- (2012) J. C. Jennette et al. ARTHRITIS AND RHEUMATISM
- Treatment of ANCA-associated vasculitides (AAV)
- (2012) Julia U. Holle et al. AUTOIMMUNITY REVIEWS
- Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review
- (2012) Ryota Sakai et al. CLINICAL RHEUMATOLOGY
- Maintenance of clinical remission in ANCA-associated vasculitis
- (2012) Raashid Luqmani Nature Reviews Rheumatology
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
- (2011) M. H. Buch et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis
- (2011) T. WADA et al. JOURNAL OF RHEUMATOLOGY
- Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody
- (2011) K. Sumida et al. RHEUMATOLOGY
- Histopathologic Classification of ANCA-Associated Glomerulonephritis
- (2010) A. E. Berden et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
- (2010) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
- (2010) Rachel B. Jones et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
- (2010) Michael Walsh et al. ARTHRITIS CARE & RESEARCH
- Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis
- (2009) M. A. Little et al. ANNALS OF THE RHEUMATIC DISEASES
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
- (2008) C Mukhtyar et al. ANNALS OF THE RHEUMATIC DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started